GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Revenue

Sino Biopharmaceutical (FRA:SMZ1) Revenue : €3,563 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Revenue?

Sino Biopharmaceutical's revenue for the six months ended in Jun. 2024 was €2,033 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €3,563 Mil. Sino Biopharmaceutical's Revenue per Share for the six months ended in Jun. 2024 was €0.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.19.

During the past 12 months, the average Revenue per Share Growth Rate of Sino Biopharmaceutical was 9.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 3.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Sino Biopharmaceutical's highest 3-Year average Revenue per Share Growth Rate was 64.10% per year. The lowest was -36.70% per year. And the median was 15.90% per year.


Sino Biopharmaceutical Revenue Historical Data

The historical data trend for Sino Biopharmaceutical's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Revenue Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,109.72 2,972.49 3,732.33 3,524.06 3,364.73

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,146.80 1,466.76 1,840.96 1,530.31 2,032.80

Competitive Comparison of Sino Biopharmaceutical's Revenue

For the Biotechnology subindustry, Sino Biopharmaceutical's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Revenue distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Revenue falls into.



Sino Biopharmaceutical Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3,563 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (FRA:SMZ1) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sino Biopharmaceutical Revenue Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

No Headlines